Q-omics provides the consensus-scored PTF1A profile across patient tissues and cancer cell-line models. PTF1A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PTF1A is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, PTF1A RNA expression shows 9,013 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, STAD, and PDAC as cancer lineages where PTF1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTF1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTF1A survival associations across molecular data types. PTF1A RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTF1A RNA expression–survival associations across cancer types. High PTF1A expression shows unfavorable associations in LIHC, KICH and BLCA, but favorable associations in LGG, UCS and STAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for PTF1A RNA expression.
This table summarizes PTF1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PTF1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTF1A shows lower tumor expression in STAD, BRCA, LUAD and THCA and higher tumor expression in KIRC and COAD. The STAD box plot shows higher PTF1A RNA expression in normal versus tumor tissue (log2 FC = −0.472, t-test p = .005).
This table shows molecular features associated with PTF1A in patient tissues and cancer cell lines. In patient samples, PTF1A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTF1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_NSCLC_LUSC.
